Share issue 2015

Offer to subscribe for shares
in Hansa Medical AB (publ)

In order to finance the necessary development of IdeS, preclinical development of a second-generation IdeS, and evaluation of the development potential for EndoS, the Board of Directors of Hansa Medical, pursuant to authorization from the shareholders meeting of Hansa Medical held on 3 June 2014, resolved on 22 February 2015 to carry out a rights issue with preemptive rights for the Company's current shareholders.

Offer in brief

For full terms and conditions, please download the Prospectus. The issue is fully underwritten through subscription undertakings and guarantees.

The number of shares in the New Share Issue

A maximum of 6,482,400 new shares with preemptive rights for the Company's shareholders will be issued pursuant to the New Share Issue.

Subscription rights and subscription price

Shareholders will receive one (1) subscription right for each share held on the record date. Four (4) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of SEK 38 per share.

Important dates

Record date 17 March 2015
Application period 19 March – 2 April 2015
Trading in subscription rights 19 March – 31 March 2015
Publication of results on or about 9 April 2015

ISIN codes

Shares: SE0002148817
Subscription rights: SE0006887550
BTA: SE0006887543

Ticker symbol


Financial calendar

Annual report 23 March 2015
Interim report for January – March 2015 16 April 2015
Annual general meeting 2 June 2015
Interim report for January – June 2015 25 August 2015
Interim report for January – September 2015 28 October 2015

For full terms and conditions, please download the Prospectus.


IdeS is a bacterial enzyme, which cleaves IgG antibodies and is a unique molecule with an entirely new treatment mechanism. IdeS inactivates all IgG specifically, quickly and effectively. IdeS has been tested for safety and efficacy in a large number of models both in vitro and in vivo. In 2013, a successful phase I study was carried out on 29 healthy test persons, which showed that IdeS has good effect and is tolerated well with an advantageous safety profile. In 2014 and 2015, a clinical phase II study was carried out with IdeS in sensitized kidney transplant patients (patients who have a surplus of HLA antibodies). Preliminary data indicates that IdeS has a very positive effect in highly sensitized patients who are on the waiting list for a kidney transplant.

The study shows that IdeS has the capacity to make sensitized patients candidates for a transplant by lowering the HLA antibodies to levels acceptable for transplantation. IdeS has treatment potential in transplants and a large number of autoimmune diseases where effective treatment methods are currently lacking. IdeS is protected by a number of different patents and has been described in a number of articles which were published in peer-reviewed scientific journals.


Prospectus PDF
Application form, with preferential rights PDF
Application form, without preferential rights PDF